G-CSF and GM-CSF in Neutropenia.
G-CSF and GM-CSF in Neutropenia.
复制标题
DOI：
10.4049/jimmunol.1500861
复制
发表时间：
2015-08-15
期刊：
影响因子：
--
通讯作者：
Corey SJ
中科院分区：
文献类型：
--
作者：
Mehta HM;Malandra M;Corey SJ
粒细胞集落刺激因子（G-CSF）和粒细胞/巨噬细胞集落刺激因子（GM-CSF）被广泛用于促进粒细胞或抗原呈递细胞（APC）的产生。美国食品和药物管理局批准G-CSF（非格司亭）用于治疗先天性和获得性血小板减少症，以及动员外周造血祖细胞进行干细胞移植。G-CSF的聚乙二醇修饰（PEG化）形式被批准用于治疗血小板减少症。当其数量低于1500/µ l时，发生临床显著的中性粒细胞减少症，使个体免疫功能低下。目前的指南建议当发热性中性粒细胞减少症的风险大于20%时使用它们。GM-CSF（沙格司亭）被批准用于干细胞移植相关的中性粒细胞减少症。由于其促进APC功能，GM-CSF在许多临床试验中被评估为免疫刺激佐剂。全世界有2 000多万人受益，美国每年的销售额超过50亿美元。
Granulocyte Colony Stimulating Factor (G-CSF) and Granulocyte/Macrophage Colony Stimulating Factor (GM-CSF) are used widely to promote the production of granulocytes or antigen presenting cells (APC). The Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired neutropenias and for mobilization of peripheral hematopoietic progenitor cells for stem cell transplantation. A polyethylene glycol modified (PEGylated) form of G-CSF is approved for the treatment of neutropenias. Clinically significant neutropenia, rendering an individual immunocompromised, occurs when their number is less than 1500/µl. Current guidelines recommend their use when the risk of febrile neutropenia is greater than 20%. GM-CSF (sargramostim) is approved for neutropenia associated with stem cell transplantation. Because of its promotion of APC function, GM-CSF is being evaluated as an immunostimulatory adjuvant in a number of clinical trials. More than 20 million persons have benefited worldwide, and more than $5 billion sales occur annually in the United States.